ATE382597T1 - Analoga von omega-3-pufas abgeleiteten lipidmediatoren und anwendungsverfahren - Google Patents

Analoga von omega-3-pufas abgeleiteten lipidmediatoren und anwendungsverfahren

Info

Publication number
ATE382597T1
ATE382597T1 AT03737135T AT03737135T ATE382597T1 AT E382597 T1 ATE382597 T1 AT E382597T1 AT 03737135 T AT03737135 T AT 03737135T AT 03737135 T AT03737135 T AT 03737135T AT E382597 T1 ATE382597 T1 AT E382597T1
Authority
AT
Austria
Prior art keywords
omega
lipid mediators
analogue
methods
application
Prior art date
Application number
AT03737135T
Other languages
English (en)
Inventor
Daniel Goodman
Michael Hanley
Stuart Bursten
Charles N Serhan
Original Assignee
Resolvyx Pharmaceuticals
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resolvyx Pharmaceuticals, Brigham & Womens Hospital filed Critical Resolvyx Pharmaceuticals
Application granted granted Critical
Publication of ATE382597T1 publication Critical patent/ATE382597T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03737135T 2002-06-17 2003-06-13 Analoga von omega-3-pufas abgeleiteten lipidmediatoren und anwendungsverfahren ATE382597T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38962202P 2002-06-17 2002-06-17

Publications (1)

Publication Number Publication Date
ATE382597T1 true ATE382597T1 (de) 2008-01-15

Family

ID=29736662

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03737135T ATE382597T1 (de) 2002-06-17 2003-06-13 Analoga von omega-3-pufas abgeleiteten lipidmediatoren und anwendungsverfahren

Country Status (7)

Country Link
US (2) US7378444B2 (de)
EP (1) EP1537069B1 (de)
JP (1) JP2005529945A (de)
AT (1) ATE382597T1 (de)
AU (1) AU2003238240A1 (de)
DE (1) DE60318456T2 (de)
WO (1) WO2003105776A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102010324B (zh) * 2000-02-16 2014-04-02 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
WO2003053423A2 (en) * 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
AU2003260687A1 (en) * 2002-04-01 2003-10-20 University Of Southern California Trihydroxy polyunsaturated eicosanoids
DE60330154D1 (de) 2002-08-12 2009-12-31 Brigham & Womens Hospital Resolvine: biotemplate zur durchführung therapeutischer anwendungen
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
EP1755537A4 (de) * 2004-04-14 2009-12-09 Univ Boston Verfahren und zusammensetzungen zur prävention oder behandlung von periodontopathien
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
AU2005262392A1 (en) * 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US8273792B2 (en) * 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
JP2009515991A (ja) 2005-11-18 2009-04-16 トラスティーズ オブ ボストン ユニバーシティ レゾルビンを使用する骨喪失の処置および防止
WO2008011085A1 (en) * 2006-07-19 2008-01-24 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of mucositis
WO2008063772A2 (en) * 2006-10-13 2008-05-29 The Brigham And Women's Hospital Inc. Resolvin d series and protectin d1 mitigate acute kidney injury
WO2008057283A2 (en) * 2006-10-26 2008-05-15 Resolvyx Pharmaceuticals, Inc. Use of resolvins for inhibition of bone loss
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
US20090137527A1 (en) * 2007-09-14 2009-05-28 Resolvyx Pharmaceuticals, Inc. Compositions and methods for modulating immune function
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
AU2014201375B2 (en) * 2007-10-12 2015-11-05 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions
US20110301239A1 (en) * 2008-04-25 2011-12-08 The Brigham And Women's Hospital, Inc. Use of novel lipid mediators to inhibit angiogenesis
EP3037401B1 (de) 2008-09-16 2020-05-06 The Brigham And Women's Hospital Inc. 14-hydroxy-docosahexaensäurenverbindungen
WO2010091226A1 (en) * 2009-02-05 2010-08-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for organ preservation
WO2011011882A1 (en) * 2009-07-29 2011-02-03 Phenomenome Discoveries Inc. Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US10383839B2 (en) 2011-06-30 2019-08-20 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
WO2015029671A1 (ja) * 2013-08-27 2015-03-05 日産自動車株式会社 内燃機関の複リンク式ピストンクランク機構
WO2017077528A2 (en) * 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
US10006925B2 (en) 2016-05-30 2018-06-26 Universal Diagnostics, S. L. Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps
EP3454907B1 (de) 2016-06-03 2020-07-22 Thetis Pharmaceuticals LLC Zusammensetzungen und verfahren in zusammenhang mit salzen von specialised pro-resolving mediatoren von entzündung
GB201611920D0 (en) * 2016-07-08 2016-08-24 Astrazeneca Ab Pharmaceutical compositions
US20220040136A1 (en) 2018-10-09 2022-02-10 University Of Rochester Treatment of vulvovaginal disorders
WO2023168245A2 (en) 2022-03-03 2023-09-07 Thetis Pharmaceuticals Llc Cyclodextrin complexes of specialized proresolving mediators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
CA2365204C (en) 1999-03-18 2009-10-27 Brigham And Women's Hospital Lipoxin compounds and their use
CN102010324B (zh) 2000-02-16 2014-04-02 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
WO2003053423A2 (en) 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
AU2003260687A1 (en) 2002-04-01 2003-10-20 University Of Southern California Trihydroxy polyunsaturated eicosanoids

Also Published As

Publication number Publication date
AU2003238240A8 (en) 2003-12-31
JP2005529945A (ja) 2005-10-06
US20080207753A1 (en) 2008-08-28
US7595341B2 (en) 2009-09-29
DE60318456D1 (de) 2008-02-14
DE60318456T2 (de) 2008-12-24
EP1537069B1 (de) 2008-01-02
AU2003238240A1 (en) 2003-12-31
US20040044050A1 (en) 2004-03-04
US7378444B2 (en) 2008-05-27
EP1537069A4 (de) 2006-01-04
WO2003105776A3 (en) 2004-09-16
WO2003105776A2 (en) 2003-12-24
EP1537069A2 (de) 2005-06-08

Similar Documents

Publication Publication Date Title
ATE382597T1 (de) Analoga von omega-3-pufas abgeleiteten lipidmediatoren und anwendungsverfahren
DE60237358D1 (de)
MX282405B (es) Acidos grasos esenciales n-3 en terapia para insuficiencia cardiaca y ataque cardiaco.
CY1105119T1 (el) Χρηση πολυακορεστων λιπαρων οξεων για την πρωτογενη προληψη σοβαρων καρδιαγγειακων επεισοδιων
ATE315388T1 (de) Therapeutische kombinationen von fettsäuren
DK0698078T3 (da) Modermælks-fedtstoferstatninger fra interesteroficerede blandinger af triglycerider
EA200701100A1 (ru) Оксилипины из полиненасыщенных жирных кислот с длинной цепью и способы их получения и применения
DK1157692T3 (da) Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
CY1111808T1 (el) Συνθεσεις εχουσες αποτελεσματα προληψης ή βελτιωσης καταστασεων ή νοσων που προκαλουνται απο εγκεφαλικη υπολειτουργια
MY104981A (en) Tailored beta-prime stable triglyceride hardstock
EP1698685A4 (de) Fettzusammensetzung
DE60000133D1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
DK1121115T3 (da) PUFA-tilskud
IT1176916B (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
RU2008108078A (ru) Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения
WO2006111633A3 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
DK1027831T3 (da) Stabiliseret fedtstofsammensætning, fremgangsmåde til fremstilling deraf og ernæringsprodukt indeholdende denne
ATE454820T1 (de) Neuartige fettpulver
NO20014341L (no) Opplösning av flerumettede fettsyrer og derivater derav ved dannelse av inklusjonssammensetninger med <gamma>-syklodekstrin ogbruk derav i farmasöytiske, kosmetiske eller matsammensetninger
DE60210382D1 (de) Zusammensetzung enthaltend einen substituirte Fettsäure oder einen substituirte Fettsäurederivate
DK0585027T3 (da) Anvendelse af fedtsyrer til behandling af abnorm vævsforkalkning
RU93049092A (ru) Лечение жирными кислотами
ATE402616T1 (de) Den pansen umgehende calcium-salze von trans- und mehrfach ungesättigten fettsäuren
CN1212867A (zh) 防治心脑血管疾病的组合物
TW360545B (en) Dermatologic preparation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties